Metabolic Syndrome and Related Diseases in Healthcare Workers

August 4, 2024 updated by: Peking Union Medical College Hospital

Metabolic Syndrome and Its Related Diseases in Healthcare Workers: Incidence, Prevalence, and Risk Factors

This study aims to investigate the incidence and prevalence of metabolic syndrome and metabolism-related diseases among healthcare workers, identify potential risk factors for these diseases, evaluate the control status of these conditions, and explore the significance of annual regular check-ups in improving metabolic-related health outcomes. All data for the study subjects are sourced from anonymized continuous records in hospital physical examinations and medical case files. The study does not involve any interventions. Upon obtaining the study data, researchers will use retrospective analysis methods to identify possible associations between risk factors and diseases.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

7432

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100730
        • Tengda Xu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Healthcare workers who were working in the hospital, including those who have retired from the hospital

Description

Inclusion Criteria:

  • Age ≥18 years
  • Healthcare workers who attend annual check-ups at Peking Union Medical College Hospital

Exclusion Criteria:

  • Presence of metabolic syndrome, hypertension, diabetes, coronary heart disease, or stroke at the time of the first physical examination between 2012 and 2022
  • Malignant neoplasm
  • Uremia
  • Liver failure
  • Moderate to severe heart failure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
the Metabolic Related Diseases in Medical Workers (MRDMW) cohort
The cohort includes all hospital employees who receive annual check-ups.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
composite endpoint of cardiovascular and cerebrovascular diseases
Time Frame: through study completion, an average of 5 years
The number of hospitalizations due to severe coronary heart disease, stroke, or sudden cardiac death. The outcome is determined if any of the first three discharge diagnoses include acute myocardial infarction, stroke, or sudden cardiac death, or if an emergency coronary stent placement or coronary artery bypass graft surgery is performed during hospitalization.
through study completion, an average of 5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
new-onset metabolic syndrome
Time Frame: through study completion, an average of 5 years

The number of individuals who did not meet the criteria for metabolic syndrome at the first examination but developed the syndrome later. The diagnostic criteria for metabolic syndrome involve meeting three or more of the following conditions:

Abdominal obesity: waist circumference ≥90 (men) or ≥85 (women) cm. Hyperglycemia: fasting blood glucose ≥6.1 or 2-hour postprandial blood glucose ≥7.8 mmol/L or previously diagnosed diabetes. Hypertension: blood pressure ≥130/85 mmHg or previously diagnosed hypertension. Elevated triglycerides: fasting triglycerides ≥1.70 mmol/L or on lipid-lowering medication. Low fasting high-density lipoprotein cholesterol (HDL-C) <1.04 mmol/L.

If waist circumference and HDL-C data are missing, abdominal obesity will be defined using the body mass index (BMI), calculated by dividing weight in kilograms by the square of height in meters (BMI ≥ 28.0 kg/m^2). Total cholesterol ≥ 5.17 mmol/L will be used as a substitute for the HDL-C indicator.
through study completion, an average of 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Peking Union Medical College Hospital

Investigators

  • Principal Investigator: Tengda Xu, Department of Health, Peking Union Medical College Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 18, 2022

Primary Completion (Actual)

August 7, 2023

Study Completion (Actual)

November 10, 2023

Study Registration Dates

First Submitted

June 6, 2024

First Submitted That Met QC Criteria

August 4, 2024

First Posted (Actual)

August 9, 2024

Study Record Updates

Last Update Posted (Actual)

August 9, 2024

Last Update Submitted That Met QC Criteria

August 4, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • K2557

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Individual patient data (IPD) could be shared with other researchers after the publication of the study. However, the sharing should be permitted by the principal investigator from email. We do not have a web address for finding more information about the individual patient data (IPD) sharing plan. And we reject any data requests with commercial intentions.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe